{"summary": "Author presents a bullish fundamental case for Thor Medical (TRMED.OL) as a self-scaling thorium isotope supplier with funded US expansion, named radiopharma customers and a tax-loss asset, while noting dilution, a disclosed short and analyst disagreement.", "reason": "The author provides a fundamental thesis for TRMED.OL based on production status, revenue potential, and specific catalysts, while acknowledging risks.", "ideas": [{"symbol": "TRMED.OL", "direction": "long", "thesis": "Thor Medical extracts Th-228, Ra-224 and Pb-212 from natural thorium without a reactor, and its AlphaOne plant is in commercial production with self-scaling feedstock and first deliveries done. The author sees NOK 330–350m revenue potential at 21k patient-dose equivalents and positive EBITDA around 2027, with a cited NOK 850m backlog and named customers including AdvanCell, Oncoinvent, RadioMedix, Telix, NucliThera, Eckert & Ziegler and Minerva. Catalysts include AdvanCell's updated phase 1b data at ESMO in October, Alpha Tau's FDA PMA top-line late 2026 or early 2027, and Oncoinvent's phase 2 interim late 2026. Main stated risks are dilution from the NOK 300m raise at NOK 4.80, a disclosed Two Sigma short, a pending subsequent offering, and the fact that drug/device approvals do not guarantee Thor wins every kilo.", "thesis_short": "Self-scaling thorium isotope supplier with funded US expansion", "quote": "Why it can be cheap: plant risk is largely behind, cash is in, US step is funded, you are not underwriting one binary readout.", "confidence": 0.78, "sentiment": 0.6, "timeframe": "3–10 years; EBITDA around 2027"}], "model": "gemini-3.1-flash-lite", "failure_count": 0, "verified": true, "extraction_model": "deepseek-flash"}
This Reddit post, published September 13, 2026, features u/Duke_Rubio discussing TRMED.OL. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Duke_Rubio · Tickers: TRMED.OL